30^th European Biotechnology Congress

This session focuses on cutting-edge genome engineering technologies and functional genomics approaches for understanding gene function and disease biology. Discussions include large-scale genomic screening, functional annotation, comparative genomics, and emerging genome engineering platforms. Experts will present breakthroughs in genome-wide screening technologies and their applications in biomedical research and therapeutic development. The track will also explore ethical considerations and future opportunities in genome manipulation and precision biology.

Advances in genomics, transcriptomics, proteomics, metabolomics, lipidomics, and integrative systems biology are transforming biotechnology research. This track explores how multi-omics data integration accelerates biomarker discovery, precision medicine, and biological network analysis. Sessions will highlight computational approaches that integrate complex biological datasets to improve disease understanding and therapeutic development. Participants will discover how systems biology is driving innovation across healthcare, agriculture, and industrial biotechnology.

RNA technologies have become one of the fastest-growing sectors in biotechnology. Topics include mRNA therapeutics, RNA editing, non-coding RNAs, circular RNA, RNA delivery platforms, and emerging RNA-based medicines beyond infectious diseases. Researchers will discuss novel RNA engineering strategies that are expanding treatment options for cancer, rare diseases, and neurological disorders. The session will also examine advances in RNA delivery systems and the future of RNA-based precision therapeutics.

This session addresses innovations in cell therapy production, viral vectors, CAR-T manufacturing, gene delivery technologies, quality control, GMP manufacturing, regulatory challenges, and commercialization of advanced therapeutic medicinal products. Experts will discuss scalable manufacturing strategies that improve product consistency, safety, and regulatory compliance. The session will also highlight emerging technologies that support the commercialization of advanced cell and gene therapies worldwide

Discover innovations in continuous bioprocessing, digital biomanufacturing, automation, process analytical technologies (PAT), Industry 4.0, robotics, and sustainable manufacturing systems for biologics and advanced therapeutics. Discussions will focus on improving manufacturing efficiency while reducing production costs and environmental impact. Participants will explore how digital transformation is creating smarter, more resilient, and highly efficient biomanufacturing facilities.

This rapidly expanding field provides alternatives to traditional animal models. Topics include patient-derived organoids, microphysiological systems, tissue chips, personalized disease modeling, toxicology testing, and precision drug development. The session will highlight innovative platforms that closely replicate human physiology for translational research and drug screening. Speakers will demonstrate how these technologies are improving predictive accuracy while supporting ethical biomedical research.

Explore how microbiome research is transforming medicine and biotechnology. Discussions include gut microbiome therapeutics, engineered probiotics, microbial ecology, live biotherapeutic products, microbiome diagnostics, and microbiome-based precision interventions. Recent discoveries linking microbial communities to human health, agriculture, and environmental sustainability will be explored. Participants will gain insights into microbiome engineering strategies that support disease prevention and therapeutic innovation.

Protein engineering has become central to therapeutic development and industrial biotechnology. This session focuses on enzyme engineering, antibody engineering, computational protein design, directed evolution, and AI-assisted protein structure prediction. Experts will present innovative computational tools that accelerate protein optimization for pharmaceutical and industrial applications. Discussions will also cover advances in enzyme discovery and next-generation biologic development.

Novel biomarkers continue to drive personalized healthcare. This track covers liquid biopsy, molecular biomarkers, companion diagnostics, early disease detection, molecular pathology, digital diagnostics, and translational biomarker validation. Sessions will examine emerging diagnostic technologies that improve clinical decision-making and patient stratification. Participants will explore how biomarker research supports earlier intervention and more effective personalized therapies.

This session highlights biotechnology innovations that modulate the immune system. Topics include immune cell engineering, therapeutic antibodies, cytokine engineering, cancer immunotherapy, autoimmune therapeutics, and next-generation biologics. Discussions will showcase cutting-edge immunotherapies that are transforming the treatment of cancer and immune-mediated diseases. The track will also explore novel engineering approaches that improve therapeutic efficacy and long-term clinical outcomes.

Rare diseases represent one of the fastest-growing biotechnology sectors. Discussions include orphan drug development, precision therapeutics, genomic diagnostics, newborn screening, personalized treatment strategies, and regulatory incentives. Experts will discuss innovative therapeutic platforms designed to address unmet clinical needs in rare genetic disorders. The session will also highlight collaborative initiatives that accelerate research, diagnosis, and patient access to advanced therapies.

This session focuses on next-generation biosensing technologies for healthcare and biotechnology. Topics include wearable biosensors, implantable devices, smart diagnostics, remote monitoring, bioelectronics, and integrated digital healthcare systems. Participants will discover how real-time monitoring technologies are improving disease management, preventive healthcare, and patient engagement. Discussions will also examine the integration of biosensors with AI and connected digital health platforms.

Biotechnology plays an essential role in achieving global sustainability goals. Discussions include carbon-negative biotechnology, bio-based materials, sustainable chemicals, industrial decarbonization, waste valorization, and circular bioeconomy innovations. The session will present innovative solutions that support environmentally responsible manufacturing and efficient resource utilization. Experts will also discuss policy initiatives and industrial strategies driving the transition toward a sustainable bioeconomy.

Synthetic biological systems and cell-free platforms are opening entirely new avenues for biotechnology. This track explores artificial cells, synthetic biomolecular systems, cell-free protein production, rapid diagnostics, and programmable biological circuits. Researchers will present emerging technologies that enable faster prototyping, flexible manufacturing, and portable diagnostic solutions. The session will also highlight future applications of synthetic biological systems across medicine, industry, and environmental biotechnology.

Bridging laboratory discoveries to clinical application remains a major priority. Topics include translational medicine, first-in-human studies, biotechnology commercialization, regulatory science, technology transfer, and successful bench-to-bedside strategies. The session will showcase collaborative models that accelerate the movement of scientific discoveries into clinical practice. Participants will explore successful case studies demonstrating effective translation of biotechnology innovations into healthcare solutions.

Designed for industry professionals and startup founders, this session explores biotech entrepreneurship, venture financing, technology commercialization, intellectual property, startup ecosystems, corporate partnerships, and investment opportunities. Discussions will provide valuable insights into building successful biotechnology ventures and attracting strategic investment. Experts will share experiences on innovation management, market entry, and sustainable growth within the global biotechnology sector.

Regulatory science has become increasingly important in biotechnology innovation. Discussions include FDA, EMA and MHRA regulations, GMP, GLP, GCP, quality by design (QbD), regulatory strategy, risk management, and global product approvals. The session will examine evolving international regulatory frameworks that facilitate safe and efficient product development. Participants will gain practical knowledge on maintaining quality standards throughout the biotechnology product lifecycle.

Explore disruptive technologies reshaping biotechnology, including quantum biotechnology, autonomous laboratories, digital biology, programmable biomaterials, advanced biofabrication, and next-generation research platforms that will define the future of life sciences. Experts will discuss breakthrough innovations expected to transform biomedical research, industrial biotechnology, and healthcare over the coming decade. The session will provide valuable perspectives on future scientific trends and emerging investment opportunities.

This concluding track examines international research collaborations, public-private partnerships, Horizon Europe initiatives, biotechnology policy, global funding opportunities, and strategies for accelerating scientific innovation through multidisciplinary collaboration. The session will emphasize the importance of cross-border partnerships in addressing complex global health, environmental, and industrial challenges. Participants will explore international funding mechanisms, collaborative research networks, and strategies for advancing biotechnology through global scientific cooperation.